The investor problem
An investor does not only need to know who else exists. They need to know whether the founder sees the real alternatives: another device, a manual workflow, a software tool, a clinical habit, a distributor preference, or a regulatory/evidence burden that shapes adoption.
A Product ID landscape keeps the answer tied to the product's actual claim boundary instead of drifting into generic market language.
What to include
- Direct product competitors.
- Adjacent products that influence customer expectations.
- Substitute workflows and current workarounds.
- Publicly cleared, approved, licensed, or listed products where relevant.
- Product-code and regulatory-lens clues.
- Known safety-history or recall signals, with clear limitations.
- Founder position: why this product should win the first wedge.
The same / different matrix
The same / different matrix is the core artifact. It keeps the founder from saying 'we have no competitors' and also keeps the investor from treating every adjacent product as a direct substitute.
| Comparison axis | Investor use |
|---|---|
| Workflow | Shows whether products compete for the same clinical or operational job. |
| Claim boundary | Shows where the company may need more evidence before using stronger language. |
| Regulatory lens | Shows review complexity without presenting a final pathway decision. |
| Public record | Shows what is source-backed and what remains assumption. |
How this becomes a workspace demo
The demo can show a founder entering a product and meeting goal, opening the Product ID landscape, selecting a competitor signal, and generating a source-backed same / different matrix plus investor Q&A prompts.
The result is a founder who can answer the investor without inventing the landscape live.
What TrueMedDevice can prepare
TrueMedDevice can prepare an investor-readiness competitive landscape: competitor buckets, source ledger, same / different matrix, claim-boundary implications, investor Q&A prompts, and open review questions.
Source ledger
What it can tell you
Public records for 510(k), Premarket Approval, De Novo, Product Classification, TPLC, recalls, and other device data families.
What it cannot decide
Whether one product is the best competitor, a valid predicate, clinically superior, commercially successful, or likely to gain share.
What it can tell you
Generic device category, product-code, regulation, and device-class clues.
What it cannot decide
Final Product ID strategy, intended-use fit, investor narrative, or market wedge.
What it can tell you
How FDA combines public premarket, postmarket, recall, and adverse-event data by product code.
What it cannot decide
Adverse-event rates, product quality, sales traction, or direct competitor ranking.
What it can tell you
Active Canadian Class II, III, and IV device licence records that may reveal licensed competitors or adjacent products.
What it cannot decide
Canadian market share, distributor readiness, or whether a licensed product is the right comparator.
Frequently asked questions
Should a founder ever say there are no competitors?
Usually no. Even if there is no identical device, there are substitute workflows, adjacent products, incumbent habits, or budget alternatives. The useful question is how direct each alternative is.
Can public device databases show market share?
No. Public device databases can show authorization, classification, and selected postmarket records. They do not prove market share or customer adoption.
What is the best first paid artifact?
A Founder Competitive Landscape Brief with source ledger, competitor buckets, same / different matrix, investor Q&A prompts, and Product ID memory writeback.
How often should the landscape be refreshed?
Refresh timing depends on the product category and fundraising or customer cadence. Monthly is often enough for a founder workspace, with event-triggered refresh when a major competitor or regulatory signal appears.
Need an investor-ready landscape around one Product ID?
Send the product and the meeting you are preparing for. We can scope a competitive landscape brief before you walk into the investor conversation.